|
1
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells - perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dalerba P, Cho RW and Clarke MF: Cancer
stem cells: Models and concepts. Annu Rev Med. 58:267–284. 2007.
View Article : Google Scholar
|
|
4
|
Costea DE, Tsinkalovsky O, Vintermyr OK,
Johannessen AC and Mackenzie IC: Cancer stem cells - new and
potentially important targets for the therapy of oral squamous cell
carcinoma. Oral Dis. 12:443–454. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Locke M, Heywood M, Fawell S and Mackenzie
IC: Retention of intrinsic stem cell hierarchies in
carcinoma-derived cell lines. Cancer Res. 65:8944–8950. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takebe N, Harris PJ, Warren RQ and Ivy SP:
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways. Nat Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar
|
|
7
|
Bolós V, Blanco M, Medina V, Aparicio G,
Díaz-Prado S and Grande E: Notch signalling in cancer stem cells.
Clin Transl Oncol. 11:11–19. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu S, Dontu G, Mantle ID, Patel S, Ahn
NS, Jackson KW, Suri P and Wicha MS: Hedgehog signaling and bmi-1
regulate self-renewal of normal and malignant human mammary stem
cells. Cancer Res. 66:6063–6071. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Noggle SA, Weiler D and Condie BG: Notch
signaling is inactive but inducible in human embryonic stem cells.
Stem Cells. 24:1646–1653. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyamoto S and Rosenberg DW: role of Notch
signaling in colon homeostasis and carcinogenesis. Cancer Sci.
102:1938–1942. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: Cell fate control and signal integration in
development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ohishi K, Varnum-Finney B, Flowers D,
Anasetti C, Myerson D and Bernstein ID: Monocytes express high
amounts of Notch and undergo cytokine specific apoptosis following
interaction with the Notch ligand, Delta-1. blood. 95:2847–2854.
2000.PubMed/NCBI
|
|
13
|
Bolós V, Grego-bessa J and de la Pompa JL:
Notch signaling in development and cancer. Endocr Rev. 28:339–363.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hansson EM, Lendahl U and Chapman G: Notch
signaling in development and disease. Semin Cancer biol.
14:320–328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iso T, Kedes L and Hamamori Y: HES and
HERP families: Multiple effectors of the Notch signaling pathway. J
Cell Physiol. 194:237–255. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Li B, Ji ZZ and Zheng PS: Notch1
regulates the growth of human colon cancers. Cancer. 116:5207–5218.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reedijk M, Odorcic S, Zhang H, Chetty R,
Tennert C, Dickson BC, Lockwood G, Gallinger S and Egan SE:
Activation of Notch signaling in human colon adenocarcinoma. Int J
Oncol. 33:1223–1229. 2008.PubMed/NCBI
|
|
18
|
Miele L, Golde T and Osborne B: Notch
signaling in cancer. Curr Mol Med. 6:905–918. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qiu M, Peng Q, Jiang I, Carroll C, Han G,
Rymer I, Lippincott J, Zachwieja J, Gajiwala K, Kraynov E, et al:
Specific inhibition of Notch1 signaling enhances the antitumor
efficacy of chemotherapy in triple negative breast cancer through
reduction of cancer stem cells. Cancer Lett. 328:261–270. 2013.
View Article : Google Scholar
|
|
20
|
Sharma A, Paranjape AN, Rangarajan A and
Dighe RR: A monoclonal antibody against human Notch1 ligand-binding
domain depletes subpopulation of putative breast cancer stem-like
cells. Mol Cancer Ther. 11:77–86. 2012. View Article : Google Scholar
|
|
21
|
Wang J, Wang C, Meng Q, Li S, Sun X, Bo Y
and Yao W: sirNA targeting Notch-1 decreases glioma stem cell
proliferation and tumor growth. Mol biol rep. 39:2497–2503. 2012.
View Article : Google Scholar
|
|
22
|
Fre S, Huyghe M, Mourikis P, Robine S,
Louvard D and Artavanis-Tsakonas S: Notch signals control the fate
of immature progenitor cells in the intestine. Nature. 435:964–968.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ward RJ and Dirks PB: Cancer stem cells:
At the headwaters of tumor development. Annu Rev Pathol. 2:175–189.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Efferth T: Stem cells, cancer stem-like
cells, and natural products. Planta Med. 78:935–942. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin JM, Wei LH, Chen YQ, Liu XX, Hong ZF,
Sferra TJ and Peng J: Pien Tze Huang induced apoptosis in human
colon cancer HT-29 cells is associated with regulation of the bcl-2
family and activation of caspase 3. Chin J Integr Med. 17:685–690.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhuang Q, Hong F, Shen A, Zheng L, Zeng J,
Lin W, Chen Y, Sferra TJ, Hong Z and Peng J: Pien Tze Huang
inhibits tumor cell proliferation and promotes apoptosis via
suppressing the STAT3 pathway in a colorectal cancer mouse model.
Int J Oncol. 40:1569–1574. 2012.PubMed/NCBI
|
|
27
|
Shen AL, Hong F, Liu LY, Lin JM, Zhuang
QC, Hong ZF and Peng J: Effects of Pien Tze Huang on angiogenesis
in vivo and in vitro. Chin J Integr Med. 18:431–436. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen A, Hong F, Liu L, Lin J, Wei L, Cai
Q, Hong Z and Peng J: Pien Tze Huang inhibits the proliferation of
human colon carcinoma cells by arresting G1/S cell cycle
progression. Oncol Lett. 4:767–770. 2012.PubMed/NCBI
|
|
29
|
Shen A, Chen Y, Hong F, Lin J, Wei L, Hong
Z, Sferra TJ and Peng J: Pien Tze Huang suppresses IL-6-inducible
STAT3 activation in human colon carcinoma cells through induction
of SOCS3. Oncol Rep. 28:2125–2130. 2012.PubMed/NCBI
|
|
30
|
Shen A, Lin J, Chen Y, Lin W, Liu L, Hong
Z, Sferra TJ and Peng J: Pien Tze Huang inhibits tumor angiogenesis
in a mouse model of colorectal cancer via suppression of multiple
cellular pathways. Oncol Rep. 30:1701–1706. 2013.PubMed/NCBI
|
|
31
|
Huang M, Zhao H, Xu W, Chu K, Hong Z, Peng
J and Chen L: Rapid simultaneous determination of twelve major
components in Pien Tze Huang by ultra-performance liquid
chromatography coupled with triple quadrupole mass spectrometry. J
Sep Sci. 36:3866–3873. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen H, Shen A, Zhang Y, Chen Y, Lin J,
Lin W, Sferra T and Peng J: Pien Tze Huang inhibits hypoxia-induced
epithelial-mesenchymal transition in human colon carcinoma cells
through suppression of the HIF-1 pathway. Exp Ther Med.
7:1237–1242. 2014.PubMed/NCBI
|
|
33
|
Shen A, Chen H, Chen Y, Lin J, Lin W, Liu
L, Sferra TJ and Peng J: Pien Tze Huang overcomes multidrug
resistance and epithelial-mesenchymal transition in human
colorectal carcinoma cells via suppression of TGF-β pathway. Evid
based Complement Alternat Med. 2014:6794362014. View Article : Google Scholar
|
|
34
|
Lin W, Zhuang Q, Zheng L, Cao Z, Shen A,
Li Q, Fu C, Feng J and Peng J: Pien Tze Huang inhibits liver
metastasis by targeting TGF-β signaling in an orthotopic model of
colorectal cancer. Oncol Rep. 33:1922–1928. 2015.PubMed/NCBI
|
|
35
|
Chen H, Feng J, Zhang Y, Shen A, Chen Y,
Lin J, Lin W, Sferra TJ and Peng J: Pien Tze Huang inhibits
hypoxia-induced angiogenesis via HIF-1 α/VEGF-A pathway in
colorectal cancer. Evid based Complement Alternat Med.
2015:4542792015. View Article : Google Scholar
|
|
36
|
Shen A, Lin W, Chen Y, Liu L, Chen H,
Zhuang Q, Lin J, Sferra TJ and Peng J: Pien Tze Huang inhibits
metastasis of human colorectal carcinoma cells via modulation of
TGF-β1/ZEb/mir-200 signaling network. Int J Oncol. 46:685–690.
2015.
|
|
37
|
Wei L, Chen P, Chen Y, Shen A, Chen H, Lin
W, Hong Z, Sferra TJ and Peng J: Pien Tze Huang suppresses the
stem-like side population in colorectal cancer cells. Mol Med Rep.
9:261–266. 2014.
|
|
38
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Longley DB, Allen WL and Johnston PG: Drug
resistance, predictive markers and pharmacogenomics in colorectal
cancer. biochim biophys Acta. 1766:184–196. 2006.PubMed/NCBI
|
|
41
|
Golebiewska A, Brons NH, Bjerkvig R and
Niclou SP: Critical appraisal of the side population assay in stem
cell and cancer stem cell research. Cell Stem Cell. 8:136–147.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Scharenberg CW, Harkey MA and Torok-Storb
B: The AbCG2 transporter is an efficient Hoechst 33342 efflux pump
and is preferentially expressed by immature human hematopoietic
progenitors. blood. 99:507–512. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nicolis SK: Cancer stem cells and
'stemness' genes in neuro-oncology. Neurobiol Dis. 25:217–229.
2007. View Article : Google Scholar
|
|
44
|
Pastrana E, Silva-Vargas V and Doetsch F:
Eyes wide open: A critical review of sphere-formation as an assay
for stem cells. Cell Stem Cell. 8:486–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
